91494-44-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure and reactivity allow it to be a valuable component in the creation of medicinal compounds with specific therapeutic targets.
Used in Organic Chemistry:
In the realm of organic chemistry, 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline is employed as a reagent or building block in various chemical reactions. The 3-chloropropanoyl group enhances the compound's versatility, facilitating its use in a range of processes that require specific functional groups for the formation of new chemical entities.
Used in Drug Development Research:
1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline is utilized in research for drug development due to its biological activity. Studies on 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline aim to understand its interactions with biological systems, which can lead to the discovery of new therapeutic agents or the enhancement of existing ones.
Used in Chemical Industry Processes:
1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline's properties make it suitable for use in various chemical industry processes where specific chemical transformations are required. Its reactivity and the presence of the 3-chloropropanoyl group allow it to participate in a multitude of reactions, contributing to the synthesis of a wide array of chemical products.

InChI:InChI=1/C12H14ClNO/c13-8-7-12(15)14-9-3-5-10-4-1-2-6-11(10)14/h1-2,4,6H,3,5,7-9H2

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 1616622-79-7 9-(5-(2-(4-methylbenzenesulfonyl)oxyethyloxy)pyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics

Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors. Among them, compound 47 possessed unique pharmacological features, exhibiting high affinities for D2, D3, 5-HT1A, 5-HT2A, and 5-HT6 receptors and low efficacy at the off-target receptors (5-HT2C, histamine H1, and adrenergic α1 receptor). Compound 47 showed dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, compound 47 resulted nonsignificantly serum prolactin levels and weight gain change compared with risperidone. Additionally, compound 47 possessed a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, compound 47 displayed procognition properties in a novel object recognition task in rats. Taken together, compound 47 may constitute a novel class of atypical antipsychotic drugs for schizophrenia.

Synthesis and application of fused heterocycle derivative

The invention belongs to the field of medical chemistry, and particularly relates to synthesis and application of a fused heterocycle derivative. The fused heterocycle derivative is of a structure shown in a general formula (I) (shown in the specification). Experiments prove that the compound can be used for treating nervous and mental diseases.

RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME

It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof.

Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one derivatives

Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against CYP1A2. Rigidification of 3 by incorporation of the ethyl group into a 5- or 6-membered ring affords compounds with a pyrroloquinolinone or pyridoquinolinone molecular scaffold (e.g., 4 and 5). It was found that these molecules are even more potent and selective CYP11B2 inhibitors than their corresponding open-chain analogues. Moreover, pyrroloquinolinone 4 exhibits no inhibition of the six most important hepatic CYP enzymes as well as a bioavailability in the range of the marketed drug fadrozole. The SAR studies disclose that subtle changes in the heterocyclic moiety are responsible for either a strong or a weak inhibition of the highly homologous 11-hydroxylase (CYP11B1). These results are not only important for fine-tuning the selectivity of CYP11B2 inhibitors but also for the development of selective CYP11B1 inhibitors that are of interest for the treatment of Cushing's syndrome and metabolic syndrome.

6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1 ).

FUSED TRICYCLIC HETEROCYCLES FOR THE TREATMENT OF SCHIZOPHRENIA

Disclosed are compounds of Formula (1), pharmaceutical compositions containing compounds of Formula (1), and the use of compounds of Formula (1) to treat central nervous system disorders, including schizophrenia and other psychotic disorders, wherein L, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 R8, R9 and R10 in Formula (1) are defined in the specification.